Epicardial Cardiac Fat-CT (EPIC-CT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 136 participants.

Also called NCT07297589

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 136 participants (planned count) (from the registry)
Sponsor
Instituto Mexicano del Seguro Social (from the registry)
Registry
  • NCT NCT07297589
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07297589. Randomized; single masking; primary purpose treatment. Start 2025-12-30 (actual); primary completion 2027-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Epicardial Cardiac Fat-CT (EPIC-CT)
Acronym
EPIC-CT
Condition
STEMI - ST Elevation Myocardial Infarction
Condition
Epicardial Fat
Intervention (Drug)
Dapagliflozin 10 MG Oral Tablet
Intervention (Drug)
Semaglutide (Rybelsus®)
Lead sponsor
Instituto Mexicano del Seguro Social (class: other government)

Record details

Record id
cardio:ct-nct07297589
Content hash
038f3036cfa866ce813f2cc2aef53ed0f4d6cdcb38831403918473b102273c95